Evidence map›Paper›PMID 34604266›Full record

ReviewFrontiers in medicine2021

Stimuli-Responsive Nanoplatform-Assisted Photodynamic Therapy Against Bacterial Infections.

You Zhou, Wenmin Deng, Mulan Mo, Dexu Luo, Houhe Liu, Yuan Jiang, Wenjie Chen, Chuanshan Xu

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race.International journal of molecular sciences · 2023
    Review
  5. Biodegradable MoORSC advances · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

You ZhouKey Laboratory of Molecular Target & Clinical Pharmacology and the State & National Medical Products Administration Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Wenmin DengDepartment of Clinical Pharmacy, The People's Hospital of Dianbai District, Maoming, China.
Mulan MoKey Laboratory of Molecular Target & Clinical Pharmacology and the State & National Medical Products Administration Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Dexu LuoKey Laboratory of Molecular Target & Clinical Pharmacology and the State & National Medical Products Administration Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Houhe LiuKey Laboratory of Molecular Target & Clinical Pharmacology and the State & National Medical Products Administration Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Yuan JiangKey Laboratory of Molecular Target & Clinical Pharmacology and the State & National Medical Products Administration Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Wenjie ChenKey Laboratory of Molecular Target & Clinical Pharmacology and the State & National Medical Products Administration Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Chuanshan XuKey Laboratory of Molecular Target & Clinical Pharmacology and the State & National Medical Products Administration Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Guangzhou Medical University · CNNational Medical Products Administration · CNState Key Laboratory of Respiratory Disease · CNThe Dialogue · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial infections are common diseases causing tremendous deaths in clinical settings. It has been a big challenge to human beings because of the antibiotics abuse and the newly emerging microbes. Photodynamic therapy (PDT) is a reactive oxygen species-based therapeutic technique through light-activated photosensitizer (PS). Recent studies have highlighted the potential of PDT as an alternative method of antibacterial treatment for its broad applicability and high efficiency. However, there are some shortcomings due to the low selectivity and specificity of PS. Growing evidence has shown that drug delivery nanoplatforms have unique advantages in enhancing therapeutic efficacy of drugs. Particularly, stimuli-responsive nanoplatforms, as a promising delivery system, provide great opportunities for the effective delivery of PS. In the present mini-review, we briefly introduced the unique microenvironment in bacterial infection tissues and the application of PDT on bacterial infections. Then we review the stimuli-responsive nanoplatforms (including pH-, enzymes-, redox-, magnetic-, and electric-) used in PDT against bacterial infections. Lastly, some perspectives have also been proposed to further promote the future developments of antibacterial PDT.

Indexed as

bacterial infectionsdrug delivery systemsnanoplatformsphotodynamic therapystimuli-responsive

Identifiers

PMID34604266
PMCPMC8482315
OpenAlexW3199955237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.